- Grace Kim brings two decades’ experience in financial strategy and business development for private and public companies
- She has a deep track record of leveraging high-impact relationships with Wall Street to optimize capital development strategy and maximize long-term value creation
-
As an experienced biopharma financial strategy partner with deep executive network across the industry, Dr Kim will contribute the following to achieve MedinCell’s objectives:
- Build strategic positioning and relationships with high profile US biopharma asset management, prominent sell-side and buy-side analysts, and broad life science stakeholders
- Advise and support US financial strategy
- Support business development
MONTPELLIER, France–(BUSINESS WIRE)–Download here the full press release
“We are very proud to welcome Grace, who is recognized as one of the best US investor relations strategists,” said Christophe Douat, CEO of MedinCell. “I’m already seeing the impact of her actions. She has a deep understanding of the US pharma and biotech capital world. I’m convinced that she will leverage this understanding to support our strategy, increase our visibility, build demand, and create long-term value. We need to build on the burgeoning interest in MedinCell from top tier US pharma and biotech institutional investors that has followed the commercial launch of UZEDY and the recognition of the first-in-class blockbuster potential of mdc-TJK, an olanzapine long-acting injectable also based on MedinCell’s technology, currently in Phase 3.”
About MedinCell
MedinCell is a commercial-stage technology pharmaceutical company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine already known and used active ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY™ (BEPO technology is licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, MedinCell currently employs more than 140 people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
Contacts
David Heuzé – Head of Communications
david.heuze@medincell.com / +33 (0)6 83 25 21 86
Media Relations
Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Investor Relations France
Louis-Victor Delouvrier/Alban Dufumier
medincell@newcap.eu / +33 (0)1 44 71 94 94
US Financial & IR Strategy
Grace Kim
grace.kim@medincell.com / +1 (646) 991-4023